{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:01:18Z","timestamp":1785268878334,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,3]]},"group-title":"Cancer Biology","reference-count":38,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA263359"],"award-info":[{"award-number":["CA263359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA213711"],"award-info":[{"award-number":["CA213711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["GM154632"],"award-info":[{"award-number":["GM154632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["GM109091"],"award-info":[{"award-number":["GM109091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA298584"],"award-info":[{"award-number":["CA298584"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Polo-like kinase 1 (PLK1) is an established therapeutic target in cancer; however, ATP-competitive kinase inhibitors have shown limited clinical success because of toxicity, acquired resistance, and incomplete inhibition of non-catalytic PLK1 functions. Targeting the Polo-box domain (PBD), which regulates PLK1 localization and substrate recognition, represents an alternative therapeutic strategy but has been hindered by the lack of selective, cell-active small molecules. Here, the optimization and biological characterization of abbapolins, a series of non-peptidic PLK1 PBD inhibitors developed using the REPLACE strategy are described. Structure-guided optimization and screening across the NCI-60 cancer cell panel identified compounds with preferential activity against prostate cancer cells. Proteomic analyses demonstrated that cellular sensitivity correlated with PLK1 protein abundance, supporting an on-target mechanism of action. Abbapolins directly engaged PLK1 in cells, induced selective degradation of endogenous PLK1, and suppressed long-term clonogenic growth. Lead compounds demonstrated favorable pharmacokinetic properties and significantly inhibited prostate tumor growth in xenograft models without detectable systemic toxicity. PLK1 abundance was significantly reduced in treated tumors and correlated with tumor response, identifying PLK1 degradation as a potential pharmacodynamic biomarker. Abbapolins also synergized with enzalutamide in castration- resistant prostate cancer cells, supporting their potential as combination therapies for advanced disease. Collectively, these studies establish selective inhibition of the PLK1 Polo-box domain as a viable therapeutic strategy, provide in vivo proof-of-concept for the REPLACE approach, and identify abbapolins as promising leads for advanced prostate cancer.<\/jats:p>","DOI":"10.64898\/2026.07.02.736204","type":"posted-content","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:50:17Z","timestamp":1783083017000},"source":"Crossref","is-referenced-by-count":0,"title":["Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy"],"prefix":"10.64898","author":[{"given":"George","family":"Merhej","sequence":"first","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurusankar","family":"Ramamoorthy","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danda","family":"Chapagai","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Esfini","family":"Farahani","sequence":"additional","affiliation":[{"name":"Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington KY, USA 40536-0298"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Kong","sequence":"additional","affiliation":[{"name":"Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington KY, USA 40536-0298"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintada Nageswara","family":"Rao","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Stafford","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Mack","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Socia","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Kumari","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hogan","sequence":"additional","affiliation":[{"name":"Biological Sciences, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niti","family":"Jani","sequence":"additional","affiliation":[{"name":"Biological Sciences, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Marjorette","family":"Pena","sequence":"additional","affiliation":[{"name":"Biological Sciences, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar","family":"Nurmemmedov","sequence":"additional","affiliation":[{"name":"CellarisBio, 9276 Scranton Road, San Diego, CA 92121, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Babic","sequence":"additional","affiliation":[{"name":"CellarisBio, 9276 Scranton Road, San Diego, CA 92121, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Chen","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington KY, USA 40536-0298"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-9565","authenticated-orcid":false,"given":"Michael D.","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campbell","family":"McInnes","sequence":"additional","affiliation":[{"name":"Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026072812201876000_2026.07.02.736204v2.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1401"},{"key":"2026072812201876000_2026.07.02.736204v2.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2653"},{"key":"2026072812201876000_2026.07.02.736204v2.3","doi-asserted-by":"crossref","unstructured":"Wyatt, M.D. and C. McInnes , Insights into the Structural Regulation of Polo-Like Kinase Activity using AlphaFold. Biorxiv, 2024.","DOI":"10.1101\/2024.10.21.618045"},{"key":"2026072812201876000_2026.07.02.736204v2.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00907-7"},{"key":"2026072812201876000_2026.07.02.736204v2.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3819"},{"issue":"10","key":"2026072812201876000_2026.07.02.736204v2.6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17460441.2024.2385603","article-title":"Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery","volume":"19","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"2026072812201876000_2026.07.02.736204v2.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3184"},{"key":"2026072812201876000_2026.07.02.736204v2.8","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-08-0801"},{"key":"2026072812201876000_2026.07.02.736204v2.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0279-9"},{"key":"2026072812201876000_2026.07.02.736204v2.10","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.2.660"},{"key":"2026072812201876000_2026.07.02.736204v2.11","doi-asserted-by":"publisher","DOI":"10.1038\/35070110"},{"key":"2026072812201876000_2026.07.02.736204v2.12","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.12.7143"},{"key":"2026072812201876000_2026.07.02.736204v2.13","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20050"},{"key":"2026072812201876000_2026.07.02.736204v2.14","doi-asserted-by":"crossref","first-page":"144097","DOI":"10.1016\/j.gene.2019.144097","article-title":"Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis","volume":"721","year":"2019","journal-title":"Gene"},{"key":"2026072812201876000_2026.07.02.736204v2.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129313"},{"key":"2026072812201876000_2026.07.02.736204v2.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813333106"},{"key":"2026072812201876000_2026.07.02.736204v2.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.006"},{"key":"2026072812201876000_2026.07.02.736204v2.18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C111.269050"},{"key":"2026072812201876000_2026.07.02.736204v2.19","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.105"},{"key":"2026072812201876000_2026.07.02.736204v2.20","doi-asserted-by":"publisher","DOI":"10.1021\/cb200551p"},{"key":"2026072812201876000_2026.07.02.736204v2.21","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.3c00269"},{"issue":"8","key":"2026072812201876000_2026.07.02.736204v2.22","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1021\/acschembio.7b01078","article-title":"Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds","volume":"13","year":"2018","journal-title":"ACS Chem Biol"},{"key":"2026072812201876000_2026.07.02.736204v2.23","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2014.918100"},{"key":"2026072812201876000_2026.07.02.736204v2.24","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2159942"},{"issue":"8","key":"2026072812201876000_2026.07.02.736204v2.25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chembiol.2017.07.009","article-title":"Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS","volume":"24","year":"2017","journal-title":"Cell Chem Biol"},{"key":"2026072812201876000_2026.07.02.736204v2.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.06.031"},{"key":"2026072812201876000_2026.07.02.736204v2.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2008.03.013"},{"issue":"12","key":"2026072812201876000_2026.07.02.736204v2.28","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1080\/15384101.2017.1325043","article-title":"Several inhibitors of the Plk1 Polo-Box Domain turn out to be non- specific protein alkylators","volume":"16","year":"2017","journal-title":"Cell Cycle"},{"key":"2026072812201876000_2026.07.02.736204v2.29","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00565"},{"key":"2026072812201876000_2026.07.02.736204v2.30","doi-asserted-by":"crossref","first-page":"113926","DOI":"10.1016\/j.ejmech.2021.113926","article-title":"Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE","volume":"227","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"14","key":"2026072812201876000_2026.07.02.736204v2.31","doi-asserted-by":"crossref","first-page":"9916","DOI":"10.1021\/acs.jmedchem.1c00133","article-title":"Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells","volume":"64","year":"2021","journal-title":"J Med Chem"},{"key":"2026072812201876000_2026.07.02.736204v2.32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac382"},{"key":"2026072812201876000_2026.07.02.736204v2.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150225"},{"issue":"1","key":"2026072812201876000_2026.07.02.736204v2.34","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41467-020-17336-9","article-title":"Proteome activity landscapes of tumor cell lines determine drug responses","volume":"11","year":"2020","journal-title":"Nat Commun"},{"key":"2026072812201876000_2026.07.02.736204v2.35","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22815"},{"key":"2026072812201876000_2026.07.02.736204v2.36","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1041689"},{"key":"2026072812201876000_2026.07.02.736204v2.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1916"},{"key":"2026072812201876000_2026.07.02.736204v2.38","doi-asserted-by":"crossref","unstructured":"Zhang, Q. , et al., The kinase PLK1 promotes Hedgehog signaling-dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer. Sci Signal, 2025. 18(878): p. eadi5174.","DOI":"10.1126\/scisignal.adi5174"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.02.736204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:20:25Z","timestamp":1785266425000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.02.736204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":38,"URL":"https:\/\/doi.org\/10.64898\/2026.07.02.736204","relation":{},"subject":[],"published":{"date-parts":[[2026,7,3]]},"subtype":"preprint"}}